

What is claimed is:

- Sub  
B1
- 10033632-122604
1. A method of inducing spinal anesthesia, comprising:  
administering spinally a small but anesthetic producing  
amount of 6-[2-(1(2)H-tetrazole-5-  
yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a  
pharmaceutically active analogue hereof to a patient in  
need of a spinal anesthetic.
  2. The method of claim 1 wherein the administering spinally  
is by intrathecal administration.
  3. The method of claim 2 wherein 6-[2-(1(2)H-tetrazole-5-  
yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a  
pharmaceutically active analogue is administered in  
conjunction with a pharmaceutically acceptable carrier for 6-  
[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-  
carboxylic acid or its biologically active analogue.
  4. The method of claim 2 wherein the dose of 6-[2-(1(2)H-  
tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid  
or a pharmaceutically active analogue administered is from  
0.1 mg to 3.0 mg.
  5. The method of claim 4 wherein the dose of 6-[2-(1(2)H-  
tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid  
or a pharmaceutically active analogue administered is from  
0.5 mg to 2.0 mg.
  6. A composition for inducing spinal anesthesia,  
comprising:  
a small but anesthetic producing amount of 6-[2-(1(2)H-  
tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic

acid or a pharmaceutically active analogue thereof in combination with a pharmaceutically acceptable carrier.

7. The composition of claim 6 wherein the administering spinally is by intrathecal administration.

8. The composition of claim 7 wherein 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue is administered in conjunction with a pharmaceutically acceptable carrier for - 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or its biologically active analogue.

9. The composition of claim 7 wherein the dose of 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue administered is from 0.1 mg to 3.0 mg.

10. The composition of claim 7 wherein the dose of 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue administered is from 0.5 mg to 2.0 mg.